Skip to content

Harrow

US · HROW #3155 by market cap
30.41 -1.72 -5.35%
Periodic snapshot; not a real-time feed. · 2026-11-20 19:30

About Harrow

Harrow, Inc. engages in the development, production, and sale of innovative medications. It operates through the following segments: Branded and ImprimisRx. The Branded segment includes activities of the company’s FDA approved ophthalmology pharmaceutical products, including the out-licensing of rights to certain branded products. The ImprimisRx segment represents activities in the company’s ophthalmology-focused pharmaceutical compounding business. The company was founded by Mark L. Baum and Robert J. Kammer on January 11, 2006 and is headquartered in Nashville, TN.

Founded
2006
CEO
Mr. Mark L. Baum
Employees
373
Headquarters
Nashville, Tennessee, United States of America
Fiscal year end
12-31
Website
harrow.com

Company profile

Exchange
US
Symbol
HROW
Market-cap rank
#3155
Market cap
1.14B
Float cap
860.08M
Shares out
37.53M
Float shares
28.28M

Sectors & themes

Cannabis & Hemp Drug Manufacturers - Specialty & Generic Fractional Shares JP

Browse all sectors & themes

Quote time 2026-11-20 19:30:06 · For reference only, not investment advice and not tailored to your situation.

Harrow discussion 0 comments

Add a comment